N,N dimethylglycine and epilepsy.

Area of Science:

• Neurology
• Clinical Pharmacology

Background:

• Epilepsy is a chronic neurological disorder characterized by recurrent seizures.
• Frequent seizures significantly impact patient quality of life and require effective treatment.
• N,N dimethylglycine (DMG) has been investigated for potential anticonvulsant properties.

Purpose of the Study:

• To evaluate the efficacy of N,N dimethylglycine (DMG) in reducing seizure frequency in institutionalized patients.
• To assess the safety and tolerability of DMG treatment in this patient population.

Main Methods:

• A randomized, double-blind, placebo-controlled trial was conducted.
• Nineteen institutionalized patients with frequent generalized, akinetic/myoclonic seizures received either placebo or DMG.
• DMG dosage was escalated from 300 mg/day to 600 mg/day over 28 days.
• Plasma DMG levels were monitored throughout the study and follow-up period.

Main Results:

• No statistically significant difference in seizure frequency was observed between the DMG and placebo groups.
• Seizure frequency remained consistent from baseline throughout the treatment period for both groups.
• No adverse events or signs of toxicity were reported for DMG treatment.

Conclusions:

• N,N dimethylglycine (DMG) did not demonstrate efficacy in reducing seizure frequency in this cohort of institutionalized patients with epilepsy.
• DMG was well-tolerated and showed no evidence of toxicity at the studied dosages.
• Further research may be needed to explore potential therapeutic roles or alternative dosing strategies for DMG in neurological conditions.